ACE and hydrops fetalis: The benefit of applying comprehensive combination therapy (including ARNI/MRA/beta-blocker/SGLT2i) instead of single-agent or dual agent therapies of the most commonly used agents (i.e. ACE-inhibitors and/or beta-blockers) has been demonstrated in meta-analyses [15, 16] and was suggested in analyses from three clinical trials (PARADIGM-HF, EMPHASIS-HF, and DAPA-HF) [13, 17, 18].